IBJNews

Court upholds Lilly patent on cancer drug Alimta

Back to TopCommentsE-mailPrintBookmark and Share

Indianapolis-based Eli Lily and Co. said a federal court judge has upheld a patent protecting one of its best-selling drugs, the cancer treatment Alimta.

A trial on the drug's compound patent, which protects its chemical makeup, started Nov. 8 and ended Monday with a ruling from the U.S. District Court for the District of Delaware, Lilly said. Generic drugmaker Teva Pharmaceuticals Industries Ltd. had challenged the patent, which protects Alimta until July 2016.

Alimita was Lilly's third-best-selling drug in the third quarter, trailing only the antipsychotic Zyprexa and the antidepressant Cymbalta. Revenue from Alimta climbed 21 percent, to $560.3 million, in the quarter, as sales in Japan rose. Alimta rang up $1.64 billion in sales during the first three quarters of 2010.

It was a welcome court win after a difficult few months for Lilly, which is facing a wave of patent expirations in coming years.

In August, a federal judge in New Jersey ruled that the company's method-of-use patent for attention deficit hyperactivity drug Strattera is invalid; Lilly is appealing that decision.  The previous month, a federal appeals court upheld a ruling that invalidated a patent on cancer drug Gemzar, which generates $750 million in U.S. sales each year.

A generic version of Gemzar launched Monday.

Gemzar is the first of several blockbuster Lilly drugs that will see their patents expire by 2013. Generic versions of Zyprexa, Cymbalta, Evista and Strattera could zap nearly half of Lilly's current sales, putting great pressure on the company to find new drugs to take their place.

Alimta is a chemotherapy drug used to treat advanced nonsquamous non-small cell lung cancer and malignant pleural mesothelioma, a cancer that affects the inside lining of the chest cavity.

Lilly said last month its third-quarter profit jumped 38 percent to $1.3 billion, as international sales climbed. But, aside from court challenges, the company also faces patent expirations for some of its key products. That includes Zyprexa next year and Cymbalta in 2013.

Analysts who follow Lilly question how it will make up for the lost revenue. Company leaders have repeatedly expressed confidence in their pipeline of drugs under development, and they also point to growth opportunities in the animal health business and emerging international markets.

 

 

 


 
 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. If what you stated is true, then this article is entirely inaccurate. "State sells bonds" is same as "State borrows money". Supposedly the company will "pay for them". But since we are paying the company, we are still paying for this road with borrowed money, even though the state has $2 billion in the bank.

  2. Andrew hit the nail on the head. AMTRAK provides terrible service and that is why the state has found a contractor to improve the service. More trips, on-time performance, better times, cleanliness and adequate or better restrooms. WI-FI and food service will also be provided. Transit from outlying areas will also be provided. I wouldn't take it the way it is but with the above services and marketing of the service,ridership will improve and more folks will explore Indy and may even want to move here.

  3. They could take the property using eminent domain and save money by not paying the church or building a soccer field and a new driveway. Ctrwd has monthly meetings open to all customers of the district. The meetings are listed and if the customers really cared that much they would show. Ctrwd works hard in every way they can to make sure the customer is put first. Overflows damage the surrounding environment and cost a lot of money every year. There have been many upgrades done through the years to help not send flow to Carmel. Even with the upgrades ctrwd cannot always keep up. I understand how a storage tank could be an eye sore, but has anyone thought to look at other lift stations or storage tanks. Most lift stations are right in the middle of neighborhoods. Some close to schools and soccer fields, and some right in back yards, or at least next to a back yard. We all have to work together to come up with a proper solution. The proposed solution by ctrwd is the best one offered so far.

  4. Fox has comments from several people that seem to have some inside information. I would refer to their website. Changed my whole opionion of this story.

  5. This place is great! I'm piggy backing and saying the Cobb salad is great. But the ribs are awesome. $6.49 for ribs and 2 sides?! They're delicious. If you work downtown, head over there.

ADVERTISEMENT